<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="PAN Biotech), 5 mM L-glutamine (Q; Life Technologies), 50 U/mL penicillin, and 50 μg/mL" exact="streptomycin" post="(PS; Life Technologies). Plasmids and transfection Plasmids encoding the"/>
 <result pre="described [9]. The transfection was performed in 50 μL Opti-MEM without" exact="phenol" post="red (Life Technologies) using TranSIT (Mirus) according to the"/>
 <result pre="of cells with cytoskeleton-modulating drugs Cells were treated with 15 μM" exact="nocodazole" post="(Sigma), 0.3 μM cytochalasin D (Sigma), or 0.15% dimethyl sulfoxide"/>
 <result pre="with 15 μM nocodazole (Sigma), 0.3 μM cytochalasin D (Sigma), or 0.15%" exact="dimethyl sulfoxide" post="(DMSO, Sigma), following previous publication [9]. The chemicals were"/>
 <result pre="MARV NCLSs transport In MARV-infected cells, the microtubule depolymerizing drug" exact="nocodazole" post="does not alter the movement of nucleocapsids, whereas the"/>
 <result pre="of nucleocapsid transport in MARV-infected cells treated with DMSO and" exact="nocodazole" post="was 379 ± 61 nm/s and 334 ± 55 nm/s, respectively [9]. A reduction in"/>
 <result pre="VP30-GFP. The cells were treated at 15 h p.t. with 0.15 μM" exact="nocodazole" post="for 3 h. Time-lapse images of cells were recorded for"/>
 <result pre="NCLS Nucleocapsid-like structure NP Nucleoprotein p.t post-transfection PS Penicillin and" exact="streptomycin" post="Q L-glutamine SD Standard deviation VLP Virus-like particle Publisher’s"/>
</results>
